GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Debt-to-Revenue

Telo Genomics (TSXV:TELO) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Telo Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Telo Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.03 Mil. Telo Genomics's annualized Revenue for the quarter that ended in Dec. 2023 was C$0.00 Mil.


Telo Genomics Debt-to-Revenue Historical Data

The historical data trend for Telo Genomics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Debt-to-Revenue Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Telo Genomics's Debt-to-Revenue

For the Diagnostics & Research subindustry, Telo Genomics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Debt-to-Revenue falls into.



Telo Genomics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Telo Genomics's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0.033) / N/A
=N/A

Telo Genomics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Telo Genomics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (TSXV:TELO) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.

Telo Genomics (TSXV:TELO) Headlines